We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Different D-Dimer Values Compared for Venous Thromboembolism Risk

By LabMedica International staff writers
Posted on 27 Sep 2015
D-dimer assays are generally evaluated according to cutoff points calibrated for of venous thromboembolism (VTE) exclusion and used to estimate the individual risk of recurrence after a first idiopathic event VTE.

The increase in age-dependent D-dimer levels has long been seen as a problem for the use of these assays in the work-up for VTE exclusion, and the assays performs poorly in the elderly population when traditional cutoff levels are adopted. More...
Different cutoff systems have therefore been proposed and prospectively investigated to rule out pulmonary embolism.

Scientist at the University Hospital of Bologna (Italy) and their colleagues screened a total of 1,010 patients, whose index VTE event was idiopathic or associated with weak risk factors, and were included in the management protocol. Persistently negative D-dimer results were recorded in 528 patients (52.8%) who permanently interrupted anticoagulation and were followed up for a maximum of two years. In contrast, the remaining 482 patients had positive D-dimer results, and at the moment of their first positive result, were recommended to continue or resume anticoagulant therapy and followed by their anticoagulation clinic.

D-dimer levels were measured using the following commercial quantitative assays: VIDAS D-dimer Exclusion (bioMerieux; Lyon, France), Innovance D-DIMER (Siemens; Deerfield, IL, USA), HemosIL D-dimer HS or HemosIL D-dimer (Instrumentation Laboratory; Milan, Italy), and (v) STA Liatest D-dimer (DiagnosticaStago; Asnieres-sur-Seine, France). As cutoff values for negative/positive results, the centers used those specific for the assay, distinguishing those with results expressed as fibrinogen equivalent units (FEU) or non-FEU (D-dimer units) and for age and gender.

The predetermined cutoff levels for each assay, specific for age (lower in subjects less than 70 years), and gender (because it is lower in males), were used. In young subjects, the D-dimer-ULtrasonography in Combination Italian Study (DULCIS) low cutoff levels resulted in half the recurrent events that would have occurred using the other criteria. In elderly patients the DULCIS results were similar to those calculated for the two age-adjusted criteria. The adoption of traditional VTE exclusion criteria would have led to positive results in the large majority of elderly subjects without a significant reduction in the rate of recurrent event.

The authors concluded that the low cutoff levels adopted in the DULCIS study for young subjects resulted in more young patients who resumed anticoagulation with subsequent increased protection from recurrent events in this population that is at high risk of recurrence. In elderly patients, the high DULCIS cutoff points led to results similar to those calculated for the two age-adjusted criteria; the adoption of VTE exclusion criteria would have led to positive results in the large majority of subjects, without a significant reduction in the rate of recurrent event. The study was published on September 12, 2015, in the journal International Journal of Laboratory Hematology.

Related Links:

University Hospital of Bologna
bioMérieux
Siemens



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: Spatial profiling of muscle-invasive bladder cancer reveals how distinct tumor cell states are organized within individual tumors (Image Credit: Shutterstock)

Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer

Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.